REVIEW article

Front. Pharmacol.

Sec. Cardiovascular and Smooth Muscle Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1585061

Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases

Provisionally accepted
Jiayi  XuJiayi Xu1Junling  LinJunling Lin1Haojian  GanHaojian Gan1Qingjian  HeQingjian He2Wenjuan  WangWenjuan Wang2Yuanhua  LiuYuanhua Liu2*
  • 1Huzhou University, Huzhou, China
  • 2The First People's Hospital of Huzhou, Huzhou, Zhejiang, China

The final, formatted version of the article will be published soon.

Bruton's tyrosine kinase inhibitors (BTKis) have made substantial impacts on the treatment of B-cell malignancies like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Therapeutic benefits aside, the clinical use of BTKis comes with several side effects, of which hypertension (HTN) is quite common and serious and of significant clinical concern. The present article will discuss the mechanisms by which the use of BTKis causes hypertension and outline strategies for managing the condition within the clinic. Studies indicate that using BTKis interferes with BTK's central role within the B-cell receptor (BCR) signaling cascade and impacts multiple downstream signaling pathways like PI3K/Akt, MAPK, and NF-κB. These changes contribute to endothelial dysfunction, increased oxidative stress, and vascular constriction, all of which are implicated in the development of hypertension. Of special concern is that oxidative stress (OS) is directly related to decreased endothelial nitric oxide (NO) production, a finding that becomes particularly relevant during the initiation of BTKi therapy. Also, BTKis affect vascular development and tone regulation by activating the Notch and RhoA/ROCK pathways, leading to increased vasoconstriction and the advancement of hypertension. In light of the possibility that BTKi-induced hypertension might jeopardize treatment tolerability and patient outcomes, this review proposes a multimodal management of the condition, including careful monitoring of blood pressure, individualized antihypertensive treatment, and possible modifications of the dosing of BTKis. Future investigations should look into the specific molecular mechanisms underpinning the development of hypertension due to BTKis as well as the effects of various antihypertensive regimens on the improvement of the cardiovascular profile of affected individuals.

Keywords: BTKi, Ibrutinib, Oxidative Stress, Hypertension, cardiovacsular diseases

Received: 28 Feb 2025; Accepted: 01 May 2025.

Copyright: © 2025 Xu, Lin, Gan, He, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yuanhua Liu, The First People's Hospital of Huzhou, Huzhou, Zhejiang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.